Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Hepatology

Retrieve available abstracts of 248 articles:
HTML format

Single Articles

    September 2022
  1. PAL S, Dey D, Chakraborty BC, Nandi M, et al
    Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
    Hepatology. 2022;76:759-774.
    PubMed     Abstract available

    August 2022
  2. WU Y, Hao X, Wei H, Sun R, et al
    TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
    Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
    PubMed     Abstract available

    July 2022
  3. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
    Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.

  4. SHEHRYAR M, Asif MZ, Umair M
    Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.

    How many steps to a feasible mouse model of hepatitis B virus infection?
    Hepatology. 2022 Jul 24. doi: 10.1002/hep.32684.

  6. ELSHEIKH R, Tien HT, Makram AM, Van NT, et al
    Acute Hepatitis of Unknown Origin in Children: Behind the Statistics.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32682.
    PubMed     Abstract available

  7. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.

  8. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.

  9. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    PubMed     Abstract available

  10. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
    Getting to HBV cure: The promising paths forward.
    Hepatology. 2022;76:233-250.
    PubMed     Abstract available

  11. WU CR, Kim HJ, Sun CP, Chung CY, et al
    Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants.
    Hepatology. 2022;76:207-219.
    PubMed     Abstract available

  12. SINGH SP, Mishra AK, Jindal A
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis - more questions than answers !
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32648.

  13. GUPTA S, Nath P, Anand AC
    Letter to the Editor: Combination treatment with IL- 1 antagonist, pentoxifylline & zinc for severe alcoholic hepatitis: Are we there yet?
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32646.

    June 2022
  14. BARNES E, Cooke GS, Lauer G, Chung RT, et al
    Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
    Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
    PubMed     Abstract available

  15. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    PubMed     Abstract available

  16. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    PubMed     Abstract available

  17. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    PubMed     Abstract available

  18. AHMAD A
    Letter to the Editor: Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32607.
    PubMed     Abstract available

  19. AHMAD A, Chaudhry HUR
    Letter to the Editor: Outcomes of pregnancy in autoimmune hepatitis: A population-based study.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32600.

  20. WANG CY, Deng Y, Li P, Zheng S, et al
    Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;75:1373-1385.
    PubMed     Abstract available

    May 2022
  21. HARRINGTON C, Krishnan S, Mack CL, Cravedi P, et al
    Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis.
    Hepatology. 2022 May 25. doi: 10.1002/hep.32591.
    PubMed     Abstract available

  22. CHUNG Y, Heneghan MA
    Reply to: Medical therapy of autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32579.

  23. EFE C, Purnak T
    Medical therapy of Autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 18. doi: 10.1002/hep.32576.

  24. EFE C, Kulkarni AV, Beretta-Piccoli BT, Magro B, et al
    Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32572.
    PubMed     Abstract available

    Another important step towards a prophylactic vaccine against hepatitis C.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32557.

  26. MULCAHY VL, Mells GF
    Commentary on Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 May 2. doi: 10.1002/hep.32547.

  27. PAPATHEODORIDI M, Tampaki M, Lok AS, Papatheodoridis GV, et al
    Risk of HBV reactivation during therapies for HCC: A systematic review.
    Hepatology. 2022;75:1257-1274.
    PubMed     Abstract available

    April 2022
  28. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.

  29. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
    Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
    PubMed     Abstract available

  30. LUCEY MR, Thursz M
    We need a new approach to clinical trials in alcohol-associated hepatitis. Is there a lesson in RECOVERY?
    Hepatology. 2022 Apr 13. doi: 10.1002/hep.32523.

    The remarkable success of the vaccine for a killer virus: Hepatitis B.
    Hepatology. 2022 Apr 11. doi: 10.1002/hep.32346.

  32. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    PubMed     Abstract available

  33. WAT C, Gane E, Yuen MF, Pavlovic V, et al
    Hepatology. 2022;75:1050-1051.

    March 2022
  34. SUNDARAM V, Jalan R
    Letter to the editor: the role of acute-on-chronic liver failure in predicting recovery in severe alcoholic hepatitis.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32495.

  35. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    PubMed     Abstract available

  36. SZABO G, Mitchell M, McClain CJ, Dasarathy S, et al
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32478.
    PubMed     Abstract available

  37. BRUCE MG, Bruden D, Hurlburt D, Morris J, et al
    Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32474.
    PubMed     Abstract available

  38. LOUKACHOV V, van Dort K, Erken R, Reesink HW, et al
    Reponse to: Letter to the Editor concerning Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32472.

  39. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
    A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
    PubMed     Abstract available

  40. HE Q, Zhang F, Shu J, Li S, et al
    Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
    PubMed     Abstract available

  41. HOWELL J, Hellard M
    Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32450.

  42. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
    Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
    Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.

    February 2022
  43. PATWA AK, Rungta S, Kumar V
    Nanoparticle therapeutic vaccine for hepatitis B: an unfulfilled dream.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32421.

  44. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.

  45. ZHANG J, Zhao T, Wei L, Wu Y, et al
    Reply: epsilonPA-44 may expand the arsenal for chronic hepatitis B combination treatment towards functional cure.
    Hepatology. 2022 Feb 24. doi: 10.1002/hep.32423.

  46. PERRILLO RP, Lin HS, Schwarz KB, Rosenthal P, et al
    Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.
    Hepatology. 2022 Feb 21. doi: 10.1002/hep.32400.
    PubMed     Abstract available

  47. LI Y, Sun Y, Liu Y, Wang B, et al
    Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32417.
    PubMed     Abstract available

  48. CHUNG YY, Heneghan MA
    Autoimmune hepatitis in pregnancy: pearls and pitfalls.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32410.
    PubMed     Abstract available

  49. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    PubMed     Abstract available

  50. TU T, Zhang H
    Viral integrations in chronic Hepatitis B infection: purposeless passenger or problematic promoter of persistence?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32388.

  51. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available

  52. WANG X, Wei Z, Cheng B, Li J, et al
    Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis.
    Hepatology. 2022;75:438-454.
    PubMed     Abstract available

    January 2022
  53. HUANG V, Lewin C, Novy P
    Leveraging universal adult vaccination as part of a multipronged approach to eliminate hepatitis B in the US.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32376.

  54. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    PubMed     Abstract available

  55. PAN CQ, Jacobson IM, Martin P, Kwo P, et al
    Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
    Hepatology. 2022 Jan 28. doi: 10.1002/hep.32366.

  56. ERKEN R, Loukachov V, van Dort K, van den Hurk A, et al
    Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32352.
    PubMed     Abstract available

  57. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
    Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
    Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
    PubMed     Abstract available

  58. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
    Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
    PubMed     Abstract available

  59. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    PubMed     Abstract available

  60. PAN JJ, Razumilava N
    Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: is less more?
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32330.

  61. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.

  62. JINDAL A
    Oral antivirals in treatment naive chronic hepatitis C infection.
    Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.

  63. GINES P, Castera L, Lammert F, Graupera I, et al
    Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
    Hepatology. 2022;75:219-228.
    PubMed     Abstract available

    December 2021
  64. COHEN C, Moraras K, Jackson M, Kamischke M, et al
    Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32304.

  65. CHEN VL, Ramrakhiani NS, Nguyen MH
    Hepatitis B screening-Universal or simplified semi-targeted but not the status quo.
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32303.

  66. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
    A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
    Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
    PubMed     Abstract available

  67. SUZUKI Y, Kakisaka K, Takikawa Y
    Letter to the Editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population based-epidemiological study.
    Hepatology. 2021 Dec 13. doi: 10.1002/hep.32280.

  68. MUSTO J, Lucey MR, Rice J
    Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32275.

  69. JINDAL A
    Letter to the editor: Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32276.

  70. WEI L, Ploss A
    Rise above the stress-Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles.
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32273.

  71. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.

  72. CAO Z, Gui H, Sheng Z, Xin H, et al
    Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32269.
    PubMed     Abstract available

  73. YURDAYDIN C, Keskin O, Yurdcu E, Caliskan A, et al
    A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32259.
    PubMed     Abstract available

  74. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
    Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
    PubMed     Abstract available

  75. HE WQ, Guo GN, Li C
    The impact of hepatitis B vaccination in United States, 1999-2018.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32265.
    PubMed     Abstract available

  76. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
    A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
    Hepatology. 2021;74:2974-2987.
    PubMed     Abstract available

  77. ISNARD P, Larue M, Pitsch A, Duong Van Huyen JP, et al
    A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease.
    Hepatology. 2021;74:3549-3551.

    November 2021
  78. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
    'Letter to the editor: Response to letter concerning our patient with post-vaccination autoimmune hepatitis like syndrome'.
    Hepatology. 2021 Nov 19. doi: 10.1002/hep.32248.
    PubMed     Abstract available

    Lettter to the editor on "Autoimmune hepatitis after COVID-19 vaccination".
    Hepatology. 2021 Nov 19. doi: 10.1002/hep.32249.
    PubMed     Abstract available

  80. WANG Y, Li Y, Zai W, Hu K, et al
    Hepatitis B Virus cccDNA Minichromosomes in Distinct Epigenetic Transcriptional States Differ in Their Vulnerability to Damage.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32245.
    PubMed     Abstract available

  81. POLITI J, Guerras JM, Donat M, Belza MJ, et al
    Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
    PubMed     Abstract available

  82. TABERNERO D, Cortese MF, Rando-Segura A, Buti M, et al
    Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32227.
    PubMed     Abstract available

  83. TERRAULT NA, Wahed AS, Feld JJ, Cooper SL, et al
    Incidence and Prediction of HBsAg Seroconversion in a Prospective Multi-ethnic HBeAg-Negative Chronic Hepatitis B Cohort.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32231.
    PubMed     Abstract available

  84. KUIPERY A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, et al
    Immunomodulation and RNA interference alter Hepatitis B Virus-specific CD8 T cell recognition of infected HepG2-NTCP.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32230.
    PubMed     Abstract available

  85. ROY A, Dhiman RK
    Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
    Hepatology. 2021;74:2909.

  86. GHANY MG, King WC, Lisker-Melman M, Lok ASF, et al
    Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.
    Hepatology. 2021;74:2395-2409.
    PubMed     Abstract available

  87. SHEN Y, Cingolani F, Malik SA, Wen J, et al
    Sex-Specific Regulation of Interferon-gamma Cytotoxicity in Mouse Liver by Autophagy.
    Hepatology. 2021;74:2745-2758.
    PubMed     Abstract available

  88. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    PubMed     Abstract available

  89. OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
    Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
    Hepatology. 2021;74:2714-2724.
    PubMed     Abstract available

    October 2021
  90. BEKKI Y, Fenig Y
    Outcomes of Severe Alcohol-Related Hepatitis with or without Early Liver Transplantation.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32219.
    PubMed     Abstract available

  91. LI M, Wong D, Vogel AS, Sack JS, et al
    Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
    PubMed     Abstract available

  92. KHANAM A, Kottilil S, Tang LSY
    PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B.
    Hepatology. 2021 Oct 24. doi: 10.1002/hep.32210.
    PubMed     Abstract available

  93. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
    Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
    PubMed     Abstract available

  94. HU K, Camila Perez-Matos M, Argemi J, Vilar E, et al
    Lipoprotein Z, A novel hepatotoxic lipoprotein, predicts outcome in alcoholic hepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32203.
    PubMed     Abstract available

  95. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available

  96. KUSHNER T, Chappell CA
    Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
    Hepatology. 2021;74:2311-2312.

  97. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    PubMed     Abstract available

    September 2021
  98. YASSEEN AS, Kwong JC, Feld JJ, Kustra R, et al
    The viral hepatitis B care cascade: A population-based comparison of immigrant groups.
    Hepatology. 2021 Sep 19. doi: 10.1002/hep.32162.
    PubMed     Abstract available

  99. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
    Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect?
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32156.
    PubMed     Abstract available

  100. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    PubMed     Abstract available

  101. RAMRAKHIANI NS, Chen VL, Le M, Yeo YH, et al
    Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.
    Hepatology. 2021 Sep 8. doi: 10.1002/hep.32142.
    PubMed     Abstract available

  102. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    PubMed     Abstract available

  103. TAUBERT R, Engel B, Diestelhorst J, Hupa-Breier KL, et al
    Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32134.
    PubMed     Abstract available

  104. DING WB, Wang MC, Yu J, Huang G, et al
    HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
    Hepatology. 2021;74:1480-1495.
    PubMed     Abstract available

  105. STERLING RK, King WC, Khalili M, Chung RT, et al
    A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
    Hepatology. 2021;74:1174-1189.
    PubMed     Abstract available

  106. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
    Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
    Hepatology. 2021;74:1148-1163.
    PubMed     Abstract available

    August 2021
  107. WANG CW, Grab J, Tana MM, Irani RA, et al
    Outcomes of Pregnancy in Autoimmune Hepatitis: A Population-Based Study.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32132.
    PubMed     Abstract available

  108. WEI L, Zhao T, Zhang J, Mao Q, et al
    Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32109.
    PubMed     Abstract available

  109. LI Y, Yu P, Kessler AL, Shu J, et al
    Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32114.
    PubMed     Abstract available

  110. YIP TC, Wong VW, Wong GL
    Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32116.
    PubMed     Abstract available

  111. JINDAL A
    Outcomes in chronic hepatitis B infection and COVID-19 - Not always benign !
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32108.
    PubMed     Abstract available

  112. OECHSLIN N, Da Silva N, Szkolnicka D, Cantrelle FX, et al
    Hepatitis E Virus RNA-Dependent RNA Polymerase is Involved in RNA Replication and Infectious Particle Production.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32100.
    PubMed     Abstract available

  113. LV XH, Yang JL, Deng K
    Letter to the Editor: unanswered questions about hepatitis B virus infection in patients with COVID-19.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32098.
    PubMed     Abstract available

  114. MUSTO J, Stanfield D, Ley D, Lucey MR, et al
    Recovery and Outcomes of Patients Denied Early Liver Transplantation (LT) for Severe Alcohol-Related Hepatitis (AH).
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32110.
    PubMed     Abstract available

  115. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
    Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
    PubMed     Abstract available

  116. TOYODA H, Leong J, Landis C, Atsukawa M, et al
    Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
    Hepatology. 2021;74:656-666.
    PubMed     Abstract available

  117. LIANG YJ, Teng W, Chen CL, Sun CP, et al
    Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
    Hepatology. 2021;74:641-655.
    PubMed     Abstract available

    July 2021
  118. LOK AS, Negro F, Asselah T, Farci P, et al
    Endpoints and new options for treatment of chronic hepatitis D.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32082.
    PubMed     Abstract available

  119. CHOLANKERIL G, Goli K, Rana A, Hernaez R, et al
    Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32067.
    PubMed     Abstract available

  120. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    PubMed     Abstract available

  121. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
    A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
    PubMed     Abstract available

  122. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available

  123. CHO Y, Szabo G
    Two Faces of Neutrophils in Liver Disease Development and Progression.
    Hepatology. 2021;74:503-512.
    PubMed     Abstract available

    June 2021
  124. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    PubMed     Abstract available

  125. BEUDEKER BJB, Janssen HLA, Boonstra A
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response?
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32003.
    PubMed     Abstract available

  126. DE PASQUALE C, Campana S, Pollicino T, Ferlazzo G, et al
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response? Author's Reply.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32004.
    PubMed     Abstract available

  127. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    PubMed     Abstract available

  128. ROBERTS H, Ly KN, Yin S, Hughes E, et al
    Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31991.
    PubMed     Abstract available

  129. YANG Z, Zhang T, Kusumanchi P, Tang Q, et al
    Transcriptomic analysis reveals the miRNAs responsible for liver regeneration associated with mortality in alcoholic hepatitis.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31994.
    PubMed     Abstract available

  130. CHOI J, Yoo S, Lim YS
    Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Hepatology. 2021;73:2155-2166.
    PubMed     Abstract available

    May 2021
  131. GANE E, Yuen MF, Kim DJ, Chan HL, et al
    Clinical Study of Single Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients with Chronic Hepatitis B.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31920.
    PubMed     Abstract available

  132. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    PubMed     Abstract available

  133. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
    Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
    PubMed     Abstract available

  134. RIEDL T, Faure-Dupuy S, Rolland M, Schuehle S, et al
    HIF1alpha-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
    Hepatology. 2021 May 15. doi: 10.1002/hep.31902.
    PubMed     Abstract available

  135. YIP TC, Wong VW, Lui GC, Chow VC, et al
    Current and past infections of hepatitis B virus do not increase mortality in patients with COVID-19.
    Hepatology. 2021 May 7. doi: 10.1002/hep.31890.
    PubMed     Abstract available

  136. LIAO H, Wang J, Liu Y, Chen J, et al
    Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?
    Hepatology. 2021;73:2075-2076.

  137. BRUNT EM, Kleiner DE, Carpenter DH, Rinella M, et al
    NAFLD: Reporting Histologic Findings in Clinical Practice.
    Hepatology. 2021;73:2028-2038.
    PubMed     Abstract available

    April 2021
  138. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available

  139. LIU Y, Wang S, Hu L
    Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31842.
    PubMed     Abstract available

  140. LEE YB, Lee J
    Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B - The Authors' reply.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31844.
    PubMed     Abstract available

  141. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
    Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
    PubMed     Abstract available

  142. ABUTALEB A, Khatun M, Clement J, Baidya A, et al
    A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India.
    Hepatology. 2021;73:1261-1274.
    PubMed     Abstract available

    March 2021
  143. GHANY MG, Lok ASF, Dienstag JL, Feinstone SM, et al
    The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
    Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830.
    PubMed     Abstract available

  144. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    PubMed     Abstract available

  145. JHAVERI R, Yee LM, Antala S, Murphy M, et al
    Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31825.
    PubMed     Abstract available

  146. GRAGNANI L, Lorini S, Marri S, Basile U, et al
    Haematological and genetic markers in the rational approach to HCV SVR patients with or without persisting cryoglobulinemic vasculitis.
    Hepatology. 2021 Mar 15. doi: 10.1002/hep.31804.
    PubMed     Abstract available

  147. EFE C, Dhanasekaran R, Lammert C, Ebi B, et al
    Outcome of COVID-19 in Patients with Autoimmune Hepatitis: an International Multi-Centre Study.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31797.
    PubMed     Abstract available

  148. GANE EJ, Kim HJ, Visvanathan K, Kim YJ, et al
    Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31795.
    PubMed     Abstract available

  149. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available

  150. COCHARD J, Bull-Maurer A, Tauber C, Burlaud-Gaillard J, et al
    Differentiated cells in prolonged hypoxia produce highly infectious native-like hepatitis C virus particles.
    Hepatology. 2021 Mar 4. doi: 10.1002/hep.31788.
    PubMed     Abstract available

  151. WONG RJ, Brosgart CL, Welch S, Block T, et al
    An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States.
    Hepatology. 2021 Mar 3. doi: 10.1002/hep.31782.
    PubMed     Abstract available

    February 2021
  152. KIM A, Wu X, Allende DS, Nagy LE, et al
    Gene deconvolution reveals aberrant liver regeneration and immune cell infiltration in alcohol-associated hepatitis.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31759.
    PubMed     Abstract available

  153. HALL EW, Schillie S, Vaughan AS, Jones J, et al
    County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756.
    PubMed     Abstract available

  154. ANTUORI A, Montoya V, Pineyro D, Sumoy L, et al
    Characterization of acute HCV infection and transmission networks in people who currently inject drugs in Catalonia: usefulness of dried blood spots.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31757.
    PubMed     Abstract available

  155. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available

  156. YOU Z, Li Y, Wang Q, Zhao Z, et al
    The Clinical Significance of Hepatic CD69(+) CD103(+) CD8(+) Resident Memory T Cells in Autoimmune Hepatitis.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31739.
    PubMed     Abstract available

  157. PARK H, Jiang X, Song HJ, Lo Re V 3rd, et al
    The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31732.
    PubMed     Abstract available

  158. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
    Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
    Hepatology. 2021;73:861-864.

  159. KIM GW, Imam H, Khan M, Mir SA, et al
    HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC.
    Hepatology. 2021;73:533-547.
    PubMed     Abstract available

  160. CHEN J, Li Y, Lai F, Wang Y, et al
    Functional Comparison of Interferon-alpha Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-alpha and Interferon-gamma Signaling.
    Hepatology. 2021;73:486-502.
    PubMed     Abstract available

  161. ZHAO X, Fan H, Chen X, Zhao X, et al
    Hepatitis B Virus DNA Polymerase Restrains Viral Replication Through the CREB1/HOXA Distal Transcript Antisense RNA Homeobox A13 Axis.
    Hepatology. 2021;73:503-519.
    PubMed     Abstract available

    January 2021
  162. DE PASQUALE C, Campana S, Barberi C, Sidoti Migliore G, et al
    Human hepatitis B virus negatively impacts the protective immune cross-talk between natural killer and dendritic cells.
    Hepatology. 2021 Jan 22. doi: 10.1002/hep.31725.
    PubMed     Abstract available

  163. HONG X, Luckenbaugh L, Perlman D, Revill PA, et al
    Characterization and Application of Precore/Core-Related Antigens in Animal Models of Hepatitis B Virus Infection.
    Hepatology. 2021 Jan 18. doi: 10.1002/hep.31720.
    PubMed     Abstract available

  164. ITO K, Okumura A, S Takeuchi J, Watashi K, et al
    Dual Agonist of Farnesoid X Receptor and G Protein-coupled Receptor TGR5 Inhibits Hepatitis B Virus Infection in Vitro and in Vivo.
    Hepatology. 2021 Jan 12. doi: 10.1002/hep.31712.
    PubMed     Abstract available

  165. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available

    December 2020
  166. AMIN OE, Colbeck EJ, Daffis S, Khan S, et al
    Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: re-modelling of antiviral and regulatory mediators.
    Hepatology. 2020 Dec 25. doi: 10.1002/hep.31695.
    PubMed     Abstract available

    November 2020
  167. HAFEZI M, Lin M, Chia A, Chua A, et al
    Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31662.
    PubMed     Abstract available

  168. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    PubMed     Abstract available

  169. ARORA V, Baweja S, Sarin SK
    Letter to the Editors: Relevance of Circulating Extracellular Vesicles Carrying Sphingolipid Cargo in Alcoholic Hepatitis: Need for more validation !
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31465.
    PubMed     Abstract available

  170. SUH GA
    Phage Therapy for Alcoholic Hepatitis.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31623.
    PubMed     Abstract available

  171. HOFMEISTER MG, Xing J, Foster MA, Augustine RJ, et al
    Factors associated with hepatitis A mortality during person-to-person outbreaks: A matched case-control study-United States, 2016-2019.
    Hepatology. 2020 Nov 20. doi: 10.1002/hep.31645.
    PubMed     Abstract available

  172. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available

  173. RAHIM MN, Ran S, Shah S, Hughes S, et al
    Safety and efficacy of budesonide during pregnancy in women with autoimmune hepatitis.
    Hepatology. 2020 Nov 14. doi: 10.1002/hep.31634.
    PubMed     Abstract available

  174. MAK LY, Cloherty G, Wong DK, Gersch J, et al
    HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy.
    Hepatology. 2020 Nov 6. doi: 10.1002/hep.31616.
    PubMed     Abstract available

  175. LEE YB, Moon H, Lee JH, Cho EJ, et al
    Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B.
    Hepatology. 2020 Nov 2. doi: 10.1002/hep.31612.
    PubMed     Abstract available

    ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection.
    Hepatology. 2020;72:1514-1517.

    October 2020
  177. ZHAO J, Chu F, Xu H, Guo M, et al
    C/EBPalpha/miR-7 controls CD4(+) T cell activation and function and orchestrates experimental autoimmune hepatitis in mice.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31607.
    PubMed     Abstract available

  178. LIU Y, Zhu P, Wang W, Tan X, et al
    MAIT Cell Dysregulation Correlates with Conjugated Bilirubin Level in Chronic Hepatitis B Virus Infection.
    Hepatology. 2020 Oct 20. doi: 10.1002/hep.31602.
    PubMed     Abstract available

  179. NOGUCHI F, Chu PS, Taniki N, Yoshida A, et al
    Long-term Observation of Cyclosporine as Second-line Therapy in Adults of Severe Acute Autoimmune Hepatitis.
    Hepatology. 2020 Oct 17. doi: 10.1002/hep.31597.
    PubMed     Abstract available

  180. KUMAR K, Dixit I
    Retreatment decision for hepatitis B flare in HBeAg negative Chronic Hepatitis B.
    Hepatology. 2020 Oct 8. doi: 10.1002/hep.31589.
    PubMed     Abstract available

  181. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available

  182. LIAW YF
    Retreatment decision for hepatitis B flare.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31586.
    PubMed     Abstract available

  183. YUAN G, Yao J, Yu J, Xie X, et al
    Letter to the Editors: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31590.
    PubMed     Abstract available

    September 2020
  184. GOH MJ, Sinn DH, Woo SY, Kim S, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2020 Sep 22. doi: 10.1002/hep.31567.
    PubMed     Abstract available

  185. LOK AS, Perrillo R, Lalama CM, Fried MW, et al
    medLow Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31554.
    PubMed     Abstract available

  186. LAPOINTE-SHAW L, Chung H, Holder L, Kwong JC, et al
    Diagnosis of Chronic Hepatitis B Peri-Complication: Risk factors and Trends over Time.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31557.
    PubMed     Abstract available

  187. TERRAULT NA, Burton J, Ghobrial M, Verna E, et al
    Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
    Hepatology. 2020 Sep 14. doi: 10.1002/hep.31551.
    PubMed     Abstract available

  188. ZHAO Q, Guo JT
    Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?
    Hepatology. 2020;72:1142-1144.

    August 2020
  189. LAU DTY, Ganova-Raeva L, Wang J, Mogul D, et al
    Precore and basal core promoter hepatitis B virus (HBV) variants are present from a young age and differ across HBV genotypes.
    Hepatology. 2020 Aug 29. doi: 10.1002/hep.31506.
    PubMed     Abstract available

  190. CANTOR A, Miller J, Zachariah P, DaSilva B, et al
    Acute hepatitis is a prominent presentation of the multisystem inflammatory syndrome in children: a single-center report.
    Hepatology. 2020 Aug 18. doi: 10.1002/hep.31526.
    PubMed     Abstract available

  191. LIAW YF
    Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: To retreat or not to retreat.
    Hepatology. 2020 Aug 18. doi: 10.1002/hep.31525.
    PubMed     Abstract available

  192. WAGNER J, Yuen L, Littlejohn M, Sozzi V, et al
    Analysis of Hepatitis B virus haplotype diversity detects striking sequence conservation across genotypes and chronic disease phase.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31516.
    PubMed     Abstract available

  193. FERGUSSON JR, Wallace Z, Connolly MM, Woon AP, et al
    Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31503.
    PubMed     Abstract available

  194. KESKIN O, Yurdaydin C
    LETTER TO THE EDITOR: Interferon is not an optimal treatment for chronic hepatitis delta but needs 'fair treatment' by us.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31501.
    PubMed     Abstract available

  195. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    PubMed     Abstract available

  196. KASTIN D, Siegel M, Anderson R, Aronsohn A, et al
    IgG 4 Autoimmune hepatitis presenting as idiopathic hypereosinophilia syndrome.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31492.
    PubMed     Abstract available

    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    PubMed     Abstract available

  198. KAPILA N, Rahman AU, Zervos XB
    Hepatology. 2020;72:788.

    July 2020
  199. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    PubMed     Abstract available

  200. CHAN HL
    Letter to the Editor: Use of Pre-genomic HBV RNA and HBcrAg to Predict Cure of Hepatitis B Virus Infection.
    Hepatology. 2020 Jul 20. doi: 10.1002/hep.31469.
    PubMed     Abstract available

  201. CAREY I, Cloherty G, Dusheiko G, Agarwal K, et al
    Reply to Letter to the Editor: Use of pre-genomic HBV RNA and HBcrAg to predict cure of hepatitis B virus infection.
    Hepatology. 2020 Jul 20. doi: 10.1002/hep.31468.
    PubMed     Abstract available

  202. SEHRAWAT TS, Shah VH, Malhi H
    Reply: Relevance of Circulating Extracellular Vesicles Carrying Sphingolipid Cargo in Alcoholic Hepatitis: Need for more validation!
    Hepatology. 2020 Jul 16. doi: 10.1002/hep.31464.
    PubMed     Abstract available

  203. SEMMLER G, Binter T, Kozbial K, Schwabl P, et al
    Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease.
    Hepatology. 2020 Jul 13. doi: 10.1002/hep.31462.
    PubMed     Abstract available

  204. JIANG L, Lang S, Duan Y, Zhang X, et al
    Intestinal virome in patients with alcoholic hepatitis.
    Hepatology. 2020 Jul 12. doi: 10.1002/hep.31459.
    PubMed     Abstract available

  205. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    PubMed     Abstract available

    Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease?
    Hepatology. 2020;72:4-6.

    June 2020
  207. PAPATHEODORIDIS GV, Voulgaris T, Papatheodoridi M, Kim WR, et al
    Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.
    Hepatology. 2020 Jun 30. doi: 10.1002/hep.31440.
    PubMed     Abstract available

  208. KIM BK, Kim SU
    Re: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Jun 29. doi: 10.1002/hep.31439.
    PubMed     Abstract available

  209. WANG F, Sun X, Wang F, Zheng H, et al
    Changing epidemiology of Hepatitis A in China: evidence from three national serological surveys and the National Notifiable Disease Reporting System.
    Hepatology. 2020 Jun 26. doi: 10.1002/hep.31429.
    PubMed     Abstract available

  210. BOLTE FJ, Schmidt HH, Schlevogt B
    Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with Multiple Sclerosis.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31435.
    PubMed     Abstract available

  211. CHASCSA DM, Ferre EMN, Hadjiyannis Y, Alao H, et al
    APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data from a Large Predominantly American Cohort.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31421.
    PubMed     Abstract available

  212. FAN X, McCullough RL, Huang E, Bellar A, et al
    Diagnostic and Prognostic Significance of Complement in Patients with Alcohol-associated Hepatitis.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31419.
    PubMed     Abstract available

  213. VIERLING JM, Kerkar N, Czaja AJ, Mack CL, et al
    Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting AASLD Guidelines.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31407.
    PubMed     Abstract available

  214. MOTOMURA D, Baetz T, Grin A, Flemming JA, et al
    Severe refractory checkpoint inhibitor-related hepatitis reversed with anti-thymocyte globulin and n-acetylcysteine.
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31396.
    PubMed     Abstract available

    May 2020
  215. MURAYAMA A, Yamada N, Osaki Y, Shiina M, et al
    N-terminal PreS1 Sequence Regulates Efficient Infection of Cell Culture-generated Hepatitis B Virus.
    Hepatology. 2020 May 23. doi: 10.1002/hep.31308.
    PubMed     Abstract available

  216. NAZZAL M, Sur S, Steele R, Khatun M, et al
    Establishment of a PDX tumor from Hepatitis C Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
    Hepatology. 2020 May 1. doi: 10.1002/hep.31298.
    PubMed     Abstract available

    April 2020
  217. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    PubMed     Abstract available

  218. CHOI J, Jo C, Lim YS
    Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31289.
    PubMed     Abstract available

  219. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available

  220. MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
    Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
    Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
    PubMed     Abstract available

  221. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available

  222. SEHRAWAT TS, Arab JP, Liu M, Amrollahi P, et al
    Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.
    PubMed     Abstract available

  223. DAFFIS S, Balsitis S, Chamberlain J, Zheng J, et al
    Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31255.
    PubMed     Abstract available

  224. YANG Y, Zhao X, Wang Z, Shu W, et al
    Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
    Hepatology. 2020;71:1154-1169.
    PubMed     Abstract available

    March 2020
  225. SZE KM, Ho DW, Chiu YT, Tsui YM, et al
    HBV-TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31231.
    PubMed     Abstract available

  226. ZENG J, Wu D, Hu H, Young JAT, et al
    Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31217.
    PubMed     Abstract available

    February 2020
  227. CHOI HSJ, Brouwer WP, Hansen BE, Janssen HLA, et al
    Hepatology. 2020;71:769.

  228. HUANG SH, Yang CJ, Hung CC
    Hepatology. 2020;71:766.

  229. ALMASI-HASHIANI A, Mansournia MA
    Letter to the Editor: Methodological Issues Regarding the Matching in Matched Case-Control Study.
    Hepatology. 2020;71:765.

  230. LIU Y, Liu H, Hu Z, Ding Y, et al
    Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination.
    Hepatology. 2020;71:463-476.
    PubMed     Abstract available

  231. STERLING RK, King WC, Wahed AS, Kleiner DE, et al
    Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
    Hepatology. 2020;71:411-421.
    PubMed     Abstract available

    January 2020
  232. CRABB DW, Im GY, Szabo G, Mellinger JL, et al
    Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.
    Hepatology. 2020;71:306-333.

    December 2019
  233. STUART L, Lambourne B, Turner P, Jones DE, et al
    HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
    PubMed     Abstract available

    October 2019
  234. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available

    September 2019
  235. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
    Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
    PubMed     Abstract available

  236. DONG B, Zhou Y, Wang W, Scott J, et al
    Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30937.
    PubMed     Abstract available

    August 2019
  237. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available

  238. ZHOU Y, Dong B, Kim KH, Choi S, et al
    Vitamin D receptor activation in liver macrophages protects against hepatic endoplasmic reticulum stress in mice.
    Hepatology. 2019 Aug 5. doi: 10.1002/hep.30887.
    PubMed     Abstract available

    July 2019
  239. MANDORFER M, Kozbial K, Schwabl P, Chromy D, et al
    Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy.
    Hepatology. 2019 Jul 31. doi: 10.1002/hep.30885.
    PubMed     Abstract available

    June 2019
  240. WANG Y, Wen H, Fu J, Cai L, et al
    Hepatocyte TRAF6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lys6- Linked Polyubiquitination of ASK1.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30822.
    PubMed     Abstract available

    May 2019
  241. GLUCHOWSKI NL, Gabriel KR, Chitraju C, Bronson RT, et al
    Hepatocyte Deletion of Triglyceride-Synthesis Enzyme DGAT2 Reduces Steatosis without Increasing Inflammation or Fibrosis.
    Hepatology. 2019 May 13. doi: 10.1002/hep.30765.
    PubMed     Abstract available

    March 2019
  242. KAO WY, Tan EC, Su CW
    Reply to comment: Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma.
    Hepatology. 2019 Mar 30. doi: 10.1002/hep.30632.
    PubMed     Abstract available

    February 2019
  243. NGUYEN MH
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30560.
    PubMed     Abstract available

  244. LAI SW, Lin CL
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30566.
    PubMed     Abstract available

    October 2018
  245. ASLAM A, Ishtiaq R, Lau DTY
    Commentary for Hepatology Elsewhere Timely administration of birth dose HBV vaccine may break the chain of perinatal transmission.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30332.
    PubMed     Abstract available

  246. LAI SW
    Proton pump inhibitors use and risk of hepatocellular carcinoma.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30302.
    PubMed     Abstract available

    August 2018
  247. LIGAT G, Schuster C, Baumert TF
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30231.
    PubMed     Abstract available

  248. FRANCA A, Filho ACML, Guerra MT, Weerachayaphorn J, et al
    Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30228.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.